The women who were most affected in Jourdain's study were also the least healthy to begin with.So the lesson,says Jourdain,is that sickly mothers should be given better care before labour, which could include taking a drug in combination with nevirapine that reduces both the chance of the baby getting HIV and the chance of resistance developing in the mother."We should improve what is in place already," says Jourdain, who works at the Harvard School of Public Health.
Another team of researchers at the conference presented similar conclusions about resistance in South African women. Infectious-disease specialist James McIntyre of the University of Witwatersrand in Johannesburg reported that if women were given nevirapine before labour and a two-drug combination therapy just afterwards, far fewer carried strains of virus resistant to nevirapine -resistance was cut at least fivefold. Jourdain called the study "preliminary,but encouraging".
In Bangkok, world health officials spoke out against Tshabalala-Msimang's stance on nevirapine. By the end of the week, the South African government had decided that although it did not recommend using nevirapine alone, it would not immediately stop dispensing it. On 14 July, the World Health Organization said that single-dose treatments should not be undermined, but alternatives should be considered where possible.
All of this spells good news for mothers and their unborn children. But many at the conference still worry about the possible effects of Tshabalala-Msimang's comments on drug policies in Africa and Asia."The confusion our minister sows is undermining prevention programmes around the world," says activist Zackie Achmat of the South African group Treatment Action Campaign. 
